In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genomic Health Inc.

Division of Exact Sciences Corp.
www.genomichealth.com

Latest From Genomic Health Inc.

MTI Outlook 2020: Medtechs Enter The Decade Of Digital, Consumers and Wellness

For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

Commercial Innovation

Exact Sciences Buys Genomic Health In $2.8Bn Expansion Deal

Cancer diagnostics company Exact Sciences is combining with Genomic Health in a major merger valued at $2.8bn. The combined company will offer two of the fastest growing brands in cancer diagnostics, Cologuard and Oncotype DX.

M & A Deals

Myriad Finishes Big Year With NICE Endorsement Of EndoPredict Breast Cancer Diagnostic

The UK's National Institute for Health and Care Excellence (NICE) has included Myriad Genetics' EndoPredict in its recommendations for guiding adjuvant chemotherapy decisions for certain early breast cancer patients. The recommendation comes just a few weeks after new data showing the long-term prognostic value of the EndoPredict test was presented at the San Antonio Breast Cancer Symposium. The company is also making progress on its Vectra rheumatoid arthritis prognostic system with the publication of a large commercial cohort and several clinical studies on development of the adjusted Vectra score.

Clinical Trials In Vitro Diagnostics

Market Intel: Liquid Biopsy II – Emerging Companies Look For Liquid Gold

The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.

Cancer Personalized Medicine
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Exact Sciences Corp.
  • Senior Management
  • Kimberly J Popovits, Chmn., Pres & CEO
    G. Bradley Cole, CFO
    Steven Shak, MD, CSO
    Frederic Pla, PhD, COO
  • Contact Info
  • Genomic Health Inc.
    Phone: (650) 556-9300
    101 Galveston Dr.
    Redwood City, CA 94063
    USA
UsernamePublicRestriction

Register